🇧🇪 ARGX.BR — argenx SE

Salud Compra fuerte
← Volver

Precio actual

815,60 EUR

Máx. histórico

912,40

63 días

Caída desde máximo

-10,61%

Rango 52 semanas

568,40 – 925,00

Variación hoy

+0,07%

Cierre anterior

815,00

Rango de hoy

812,40 – 835,80

Volumen hoy

109.168

Peor caída histórica

-39,26%

21/07/2023 → 21/12/2023

Recuperado en 262 días

Volatilidad anualizada ⓘ

43,77%

Información
Nombre completo
argenx SE
Divisa
EUR
Mercado
Brussels
Sector
Salud
Industria
Biotechnology
Empleados
1.863
PER ⓘ
32,82 (puede no estar actualizado)
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
998,93 EUR (puede no estar actualizado)
Primera cotización
10/07/2014
Precio actualizado
hace 1 día
Sobre la empresa

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave's disease, myositis, Sjögren's disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
30/03/2015 9,18 9,35 9,12 9,12 -0,65% 2,51% 7.537
27/03/2015 9,11 9,38 9,11 9,18 -3,06% 2,96% 8.953
26/03/2015 9,61 9,61 9,41 9,47 -1,76% 2,08% 6.183
25/03/2015 9,74 9,86 9,63 9,64 -1,13% 2,36% 6.467
24/03/2015 9,56 9,88 9,56 9,75 +0,72% 3,35% 7.315
23/03/2015 9,87 9,87 9,60 9,68 -1,22% 2,74% 10.822
20/03/2015 9,88 9,88 9,76 9,80 -0,91% 1,21% 9.652
19/03/2015 9,36 9,91 9,30 9,89 +3,13% 6,52% 21.373
18/03/2015 9,05 9,60 9,04 9,59 +4,81% 6,19% 9.190
17/03/2015 9,37 9,37 9,15 9,15 -2,56% 2,35% 4.378
16/03/2015 9,46 9,50 9,34 9,39 +0,97% 1,69% 5.731
13/03/2015 9,50 9,50 9,30 9,30 -1,38% 2,11% 4.350
12/03/2015 9,55 9,55 9,24 9,43 +0,75% 3,25% 5.925
11/03/2015 9,46 9,46 9,18 9,36 +1,19% 2,96% 3.663
10/03/2015 9,65 9,65 9,03 9,25 -4,15% 6,42% 22.555
09/03/2015 10,00 10,00 9,52 9,65 -3,31% 4,80% 14.046
06/03/2015 9,65 10,15 9,57 9,98 +5,83% 6,01% 44.505
05/03/2015 9,29 9,84 9,29 9,43 +4,78% 5,92% 51.497
04/03/2015 8,56 9,24 8,55 9,00 +7,40% 8,06% 37.928
03/03/2015 8,40 8,60 8,38 8,38 -1,76% 2,62% 11.762
02/03/2015 8,53 8,65 8,49 8,53 +1,43% 1,88% 9.757
27/02/2015 8,12 8,45 8,12 8,41 +3,70% 4,06% 8.386
26/02/2015 8,25 8,25 8,02 8,11 -1,70% 2,79% 10.707
25/02/2015 8,26 8,36 8,25 8,25 -0,60% 1,33% 4.029
24/02/2015 8,50 8,50 8,24 8,30 -1,07% 3,06% 13.882
23/02/2015 8,54 8,54 8,29 8,39 +0,60% 2,93% 15.489
20/02/2015 8,57 8,59 8,34 8,34 -2,11% 2,92% 7.506
19/02/2015 8,68 8,85 8,51 8,52 +0,12% 3,92% 44.017
18/02/2015 7,90 8,63 7,90 8,51 +9,38% 9,24% 63.979
17/02/2015 7,78 7,93 7,76 7,78 +0,00% 2,19% 28.429